VEGFA and colorectal cancer: For instance, in the randomized phase 2 CAPability-01 trial, researchers assessed the effectiveness of combining the PD-1 monoclonal antibody Sintilimab with the HDACi Tucidinostat, with or without the anti-VEGF monoclonal antibody Bevacizumab, in patients with unresectable chemotherapy-refractory locally advanced or metastatic microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer.